GLP-1 Drugs May Reach Only Half of Eligible Patients
Eli Lilly's CEO says structural barriers will cap GLP-1 weight-loss drug adoption at 40-50% of eligible patients, mirroring statin penetration rates.
Eli Lilly
3 articles tagged "Eli Lilly"
Novo Nordisk Faces Investor Pressure at 2026 Annual Meeting
Novo Nordisk faces shareholder scrutiny as its stock drops 45% since CEO ouster, while rival Eli Lilly surges to a $1 trillion market cap.
Eli Lilly's Retatrutide Cuts Blood Sugar & Weight in Trial
Eli Lilly's triple-G drug retatrutide showed significant HbA1C and weight reductions in type 2 diabetes patients at 40 weeks in a 2026 late-stage trial.